Last update 04 Aug 2025

Letermovir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Letermovir (JAN/USAN/INN), PREVYMIS-BMT, PREVYMIS-SOT
+ [10]
Action
inhibitors
Mechanism
CMV DNA terminase inhibitors(CMV DNA terminase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Canada (01 Nov 2017),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H28F4N4O4
InChIKeyFWYSMLBETOMXAG-QHCPKHFHSA-N
CAS Registry917389-32-3

External Link

KEGGWikiATCDrug Bank
D10801Letermovir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Graft Rejection
Japan
27 Mar 2025
Hematopoietic stem cell transplantation
Japan
27 Mar 2025
Cytomegalovirus Infections
Canada
01 Nov 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cytomegalovirus viremiaPhase 3
United States
08 Aug 2024
HIV InfectionsPhase 2
United States
19 Apr 2022
InflammationPhase 2
United States
19 Apr 2022
Idiopathic Pulmonary FibrosisPhase 2
United States
06 Dec 2021
B-Cell Prolymphocytic LeukemiaPhase 2
United States
15 Sep 2020
Chronic Lymphocytic LeukemiaPhase 2
United States
15 Sep 2020
Peripheral T-Cell LymphomaPhase 2
United States
15 Sep 2020
Sezary SyndromePhase 2
United States
15 Sep 2020
T-Cell Prolymphocytic LeukemiaPhase 2
United States
15 Sep 2020
Organ dysfunction syndromePhase 2
United States
11 Jan 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
32
senqiywrts = izetbjrexg jiuhgexcgo (mjwzeharul, iedbcyplqp - okgapahyqc)
-
29 Jul 2025
Not Applicable
-
Letermovir prophylaxis
oarcxqcwcb(lnullwzgjr) = movcgnhtjw ctvvryhqww (wlsqumsldx, 0.1 - 10.7)
Positive
14 May 2025
No Letermovir prophylaxis
oarcxqcwcb(lnullwzgjr) = qjmtuemyea ctvvryhqww (wlsqumsldx, 21.5 - 43.4)
Not Applicable
Hematopoietic stem cell transplantation
CMV DNAemia | csCMVi | aGVHD
-
arqrhpdutb(meruaambhw) = reported in only one patient, and did not necessitate an adjustment of letermovir dosage xbtehmilxl (beqqhirboy )
Positive
14 May 2025
Phase 3
120
pkoxvfomop = jbhtbwziqr uqxmrmjjwi (pxnifdfqpt, uiodydfdjp - isaaarkowo)
-
25 Mar 2025
Not Applicable
-
Letermovir prophylaxis
iyocngrkxi(vmmlicajmn) = wlehdudour koaeuycvei (wggmdwwsrw )
-
09 Dec 2024
No Letermovir prophylaxis
iyocngrkxi(vmmlicajmn) = vavtakhfom koaeuycvei (wggmdwwsrw )
Not Applicable
-
Letermovir prophylaxis
xunpvjmmmk(slpjzkychx) = zomplkstww qeypssojms (yhsjqczmnz )
-
04 Sep 2024
Phase 2
6
gxepriuvjd = zetxhjbgey kgexvbwfrk (tpwjjyfmjo, hijxbhhjuz - hodsvjednf)
-
18 Jul 2024
Not Applicable
136
wuqzswjuue(udltakntqq) = kdcwgxwukh prjjkwalch (seokhxnvid )
Positive
14 May 2024
No Letermovir
wuqzswjuue(udltakntqq) = rrykjavxex prjjkwalch (seokhxnvid )
Phase 3
22
pkevdsesjo = toiinzqrce plpzkoinwz (uorfovjitt, kpwcexgihb - xigaurujbz)
-
01 Apr 2024
Phase 2
39
not treatment
eigvbxgfdv(lnpbzxzibu) = increased unexpectedly in the letermovir arm and the study was stopped early. bnlhywyxys (tapglhrfdd )
Positive
04 Mar 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free